DR30206: A Comprehensive Analysis of a Novel Trispecific Antibody for the Treatment of Solid Tumors

1.0 Executive Summary

DR30206 is an investigational, first-in-class trispecific antibody fusion protein engineered to simultaneously target three critical pathways that govern the tumor microenvironment (TME): Programmed death-ligand 1 (PD-L1), vascular endothelial growth factor (VEGF), and transforming growth factor-beta (TGF-β).[1] Developed by Zhejiang Doer Biologics Co., Ltd., this agent is built upon the company's proprietary MultipleBody® platform and embodies a sophisticated therapeutic hypothesis: that comprehensive, simultaneous blockade of these interconnected pathways can synergistically dismantle tumor defenses, overcome resistance to existing immunotherapies, and elicit potent, durable anti-tumor responses.[1]

The molecule's innovative architecture features the well-established anti-VEGF antibody Bevacizumab as its structural backbone, with an anti-PD-L1 single-domain antibody (VHH) and a TGF-β "trap" fused to its termini.[3] Preclinical studies have provided a strong proof-of-concept, demonstrating that DR30206 possesses superior anti-tumor activity compared not only to monotherapies but also to the combination of separate anti-PD-L1 and anti-VEGF antibodies, suggesting a true synergistic effect conferred by the single-molecule format.[3]

The clinical development program for DR30206 is proceeding on an aggressive, parallel track. A Phase 1 monotherapy trial (NCT06132828) is evaluating its safety and preliminary efficacy in a broad population of patients with advanced solid tumors, while a Phase Ib/IIa trial (NCT07056777) is assessing its potential in combination with standard chemotherapy for gastrointestinal cancers.[5] This strategy is designed to rapidly define the drug's therapeutic window and identify its most promising clinical applications.